FDA Approves Landmark Sickle Cell Gene Therapies
FRIDAY, Dec. 8, 2023 (HealthDay News) — The U.S. Food and Drug Administration on Friday approved two milestone gene therapies for sickle cell disease, including the first treatment ever approved that uses gene-editing technology. Casgevy, developed by Vertex Pharmaceuticals of Boston and CRISPR Therapeutics of Switzerland, is the first medicineContinue Reading